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ADIPOSE-DERIVED STROMAL CELLS
Senescence and quiescence in adipose-derived stromal cells:
Effects of human platelet lysate, fetal bovine serum and hypoxia
REBEKKA HARARY SØNDERGAARD, BJARKE FOLLIN, LISBETH DROZD LUND,
MORTEN JUHL, ANNETTE EKBLOND, JENS KASTRUP &
MANDANA HAACK-SØRENSEN
Cardiology Stem Cell Centre,The Heart Centre, Rigshospitalet, Copenhagen University Hospital,
Copenhagen, Denmark
Abstract
Background aims. Adipose-derived stromal cells (ASCs) are attractive sources for cell-based therapies.The hypoxic niche of
ASCs in vivo implies that cells will benefit from hypoxia during in vitro expansion. Human platelet lysate (hPL) enhances
ASC proliferation rates, compared with fetal bovine serum (FBS) at normoxia. However, the low proliferation rates of FBS-
expanded ASCs could be signs of senescence or quiescence.We aimed to determine the effects of hypoxia and hPL on the
expansion of ASCs and whether FBS-expanded ASCs are senescent or quiescent. Methods. ASCs expanded in FBS or hPL
at normoxia or hypoxia until passage 7 (P7), or in FBS until P5 followed by culture in hPL until P7, were evaluated by
proliferation rates, cell cycle analyses, gene expression and β-galactosidase activity. Results. hPL at normoxia and hypoxia
enhanced proliferation rates and expression of cyclins, and decreased G0/G1 fractions and expression of p21 and p27, com-
pared with FBS. The shift from FBS to hPL enhanced cyclin levels, decreased p21 and p27 levels and tended to decrease
G0/G1 fractions. Conclusion. Hypoxia does not add to the effect of hPL during ASC expansion with regard to prolifera-
tion, cell cycle regulation and expression of cyclins, p21 and p27. hPL rejuvenates FBS-expanded ASCs with regard to cell
cycle regulation and expression of cyclins, p21 and p27.This indicates a reversible arrest.Therefore, we conclude that ASCs
expanded until P7 are not senescent regardless of culture conditions.
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Introduction
Over the years, adipose-derived stromal cells (ASCs)
have gained increasing attention because of their
relatively high abundance, easier accessibility and
higher proliferation rates in vitro, compared with
mesenchymal stromal cells from bone marrow
(BMSCs) [1].
ASCs reside in a hypoxic niche in vivo, which sug-
gests that hypoxic conditions during in vitro expansion
might be beneficial [2]. Indeed, hypoxia has been
shown to enhance in vitro proliferation rates of ASCs
cultured in fetal bovine serum (FBS) [3–5]. Human
platelet lysate (hPL) enhances ASC proliferation rates,
compared with FBS.Thus, a combination of hypoxia
and hPL might enhance ASC proliferation rates and
prevent senescence during culture expansion [2,4–6].
However, the low proliferation rates of ASCs ex-
panded in FBS at normoxia could potentially be due
to the presence of quiescent or slowly proliferating cells,
rather than senescent cells.
Regulation of ASC proliferation is mediated by
cyclins, which drive progression through the cell cycle.
Of these, cyclin E has been shown to be essential and
rate-limiting for transition through the first check-
point, known as G1/S [7,8]. Quiescent and slowly
proliferating cells share a number of common fea-
tures including large proportions of cells in G0/G1
phase, high expression levels of p21 and p27, and re-
versibility. This means that quiescent and slowly
proliferating cells will reinitiate or increase prolifera-
tion and decrease the proportions of cells in G0/G1
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phase in response to mitogenic stimulation [9,10]. In
the case of quiescent cells, reversibility is dependent
on transcription factor HES1, which suppresses se-
nescence and terminal differentiation [11].
In contrast to the reversible cell states, the cell
cycle arrest of senescence is essentially irreversible.
Once senescent, cells will not re-enter the cell cycle
if the senescence-inducing stimuli are terminated
[12], nor will senescent cells respond to mitogenic
stimulation [13]. The features of senescent cells
include high expression levels of p21 and p16INK4A,
and increased senescence-associated β-galactosidase
activity [9,14,15].
Because senescent cells acquire functional abnor-
malities, their presence in a clinical cell product could
compromise efficacy [16,17].Therefore, we have, with
modifications, adapted the excellent study design of
Griffiths et al. to distinguish reversible cell states from
irreversible senescence in our FBS cultures [18]. Grif-
fiths et al. demonstrated that hPL completely
rejuvenates middle passage (P6–P8) BMSCs ex-
panded in FBS, whereas late passage (P15-16) BMSCs
only respond transiently to a shift to hPL before their
proliferation is significantly impaired [18]. This sug-
gests that BMSCs P6–P8 are reversibly arrested, while
BMSCs P15–16 are irreversibly arrested, and hence
senescent.
At our stem cell centre, FBS-expanded ASCs and
BMSCs used for clinical trials do not exceed P3
[19–22].We have chosen to expand ASCs cultured in
FBS for two additional passages (until P5) before sub-
jecting them to our test for reversibility. In addition,
we have included the combination of hypoxia and clin-
ically approved hPL to determine the optimal culture
conditions for clinical ASC production.
The aim of this study was to investigate whether
our ASC cell product is devoid of senescent cells, re-
gardless of the media supplements FBS and hPL and
oxygen tension. This was investigated based on pro-
liferation rates, cell cycle analysis, gene expression and
senescence-associated β-galactosidase activity.
Methods
Experimental design
ASCs isolated from the stromal vascular fraction (SVF)
of adipose tissue were cultured in two clinically ap-
proved complete media containing either hPL or FBS,
at normoxic or hypoxic (5% O2) conditions. ASCs were
expanded until P7 at the following conditions: (i) FBS,
(ii) FBS hypoxia, (iii) hPL, (iv) hPL hypoxia, (v) P5
FBS shifted to hPL and (vi) P5 FBS hypoxia shifted
to hPL hypoxia (Figure 1).
To avoid contact inhibition-induced quiescence,
cell cycle analysis was performed and RNA was ex-
tracted from a pool of sub-confluent ASCs.
Lipoaspirate preparation and SVF isolation
Lipoaspirate was obtained from three healthy donors
(one male, two females, aged 23–55 years, mean age
35 years). The use of lipoaspirate from healthy vol-
unteers was approved by the National Ethical
Committee protocol no. H-3-2009-119. All donors
agreed to and signed the informed written consent.
Approximately 100 mL lipoaspirate was obtained
from liposuction of subcutaneous abdominal fat per-
formed under local anaesthesia.The lipoaspirate was
washed 2–4 times with phosphate buffered saline (PBS)
pH 7.4 (Gibco, Life Technologies) to remove resid-
ual blood. The adipose tissue was digested by
incubation with 0.6 PZ U/mL collagenase NB 4
(Serva) dissolved in HBSS (2 mmol/L Ca2+, LifeTech-
nologies) at 37°C for 45–55 min, at constant rotation.
The collagenase was inactivated with complete medium
containing 10% FBS (Irradiated, Gibco, Life Tech-
nologies), followed by filtration through a 100-µm mesh
(Steriflip Filtration System, Millipore). Cells were cen-
trifuged for 10 min at 1200g, resuspended in complete
medium containing FBS or hPL and cell number and
viability were measured using NucleoCounter NC-
100 (Chemometec) according to manufacturer’s
instructions.
Cell culture
SVF cells were seeded in T-75 flasks (Thermo Fisher
Scientific) at a density of 4.5 × 106 cells/flask in com-
plete medium containing Minimum Essential Medium
alpha (αMEM) (Gibco, Life Technologies) with 1%
penicillin/streptomycin (Gibco, LifeTechnologies) and
one of the following supplements: 10% FBS or 5%
hPL (Stemulate, Cook Regentec).The FBS batch has
previously been used in our clinical studies [19–22],
and thus it has been pre-qualified for ASC culture.
SVF cells were incubated at normoxic condi-
tions (37°C, 5% CO2, 21% O2, humidified air). On
the third day of culture, cells were washed twice with
PBS to remove non-adherent cells. Subsequently,
medium was changed every 3–4 days.
Figure 1. Flow chart of the experimental design.
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ASCs P1 and subsequent passages were cultured
at either normoxic or hypoxic (37°C, 5% CO2, 5%
O2, humidified air) conditions.
Upon reaching ≥80% confluence, cells were har-
vested by incubation with 3 mLTrypLE Select (Gibco,
Life Technologies) for 10 min, at normoxic condi-
tions. TrypLE was inactivated with 7 mL complete
medium containing FBS or hPL,and cells were counted
and re-seeded at a density of 3.5 × 105 cells/T-75 flask
in 15 mL complete medium containing FBS or hPL.
Proliferation
Population doublings (PDs) were calculated from P1
using the formula: PD = (log N—log N0)/log 2, where
N is the number of harvested cells and N0 is the
number of seeded cells. Cumulative population
doublings (cPDs) were defined as the sum of all suc-
cessive PDs.
Phenotypic characterization
Cells were characterized according to the guidelines es-
tablished by the International Society for CellularTherapy
(ISCT) and the International Federation for Adipose
Therapeutics and Science (IFATS) at the end of P1
[23,24]. Cells were washed in flow cytometry PBS con-
taining fluorescence activated cell sorting (FACS) PBS
(Hospital Pharmacy), 1% ethylenediaminetetraacetic
acid (EDTA) (Hospital Pharmacy) and 10% newborn
calf serum (Gibco, Life Technologies) and incubated
with antibodies (1.5 × 105 cells per sample) for 30 min
at room temperature, protected from light. The anti-
bodies were as follows: CD105-phycoerythrin (PE)
(clone 166707, R&D Systems), CD90-fluorescein
isothiocyanate (FITC) (F15-42-1-5), CD13-
phycoerythrin-Texas Red (ECD) (Immu103.44),
CD34-allophycocyanin (APC) (581), HLA-DR-FITC
(B8.12.2), CD19-ECD (J3-119), CD14-PE-Cyanin 7
(PECy7) (RMO52), CD29-FITC (K20) (all from
Beckman Coulter), and CD73-PE (AD2), CD45-
FITC (2D1), CD31-FITC (WM59), CD36-FITC
(CB38), CD106-FITC (51-10C9), CD166-PE (3A6)
all from BD Biosciences. After incubation, cells were
washed in flow cytometry PBS, re-suspended in PBS
and analyzed on a Navios flow cytometer (Beckman
Coulter), using a fluorescence minus one protocol. Cell
viability was determined by labeling with 1 µL Sytox
Blue (LifeTechnologies) for 5 min, before analysis. At
least 5000 live cells were acquired per sample.Data were
analyzed with Navios software and Kaluza (Beckman
Coulter),with discrimination of dead cells and doublets.
Cell cycle assay
Sub-confluent cells (5 × 105) were fixed in 70% ice-
cold ethanol, added drop-wise while vortexing and
incubated for 30 min, on ice. After fixation, cells were
washed in ice-cold flow cytometry PBS and centri-
fuged for 10 min, at 800g. Cells were incubated with
500 µL Propidium iodide/RNase staining buffer (BD
Biosciences) for 15 min at room temperature, pro-
tected from light. Following incubation, cells were
washed, re-suspended in flow cytometry PBS and ana-
lyzed on a BD FACS Canto II (BD Biosciences).Ten
thousand cells were acquired per sample. Data anal-
ysis was performed using FlowJo version 10 software
(Treestar). Cells were gated on forward and side scatter,
and cell debris was excluded.The percentage of cells
in G0/G1-, S- and G2/M-phase were calculated as a
function of DNA content by fitting data to the Dean-
Jett-FOX model (see Supplementary Figure S1).
Quantitative polymerase chain reaction
Total RNA was extracted from sub-confluent cells
using Qiagen RNeasy Mini Kit (Qiagen) according to
manufacturer’s protocol. RNA purity was validated
using a NanoDrop 1000 Spectrophotometer (Thermo
Scientific) with A260/A280 and A260/A230 minimum
criteria of 1.7–2.2.
cDNA synthesis was prepared using AffinityScript
(Stratagene, Agilent Technologies) according to man-
ufacturer’s protocol.
Quantitative polymerase chain reaction (qPCR) was
performed using Brilliant II SYBR Green QPCR master
mix with low reference dye ROX (Agilent Technolo-
gies), as described previously [25]. cDNA was diluted
in Tris-EDTA buffer (Sigma-Aldrich) and subse-
quently in RNase-DNase-free water (5 Prime) and
added to each well along with primers (Life Tech-
nologies), SYBR Green and RNase-DNase-free water,
giving a total reaction volume of 25 µL/well. qPCR
reactions were performed on an Mx3000 (Stratagene,
AH-diagnostics), and results were collected using
Mx3000 version 4.0 software forWindows (Stratagene,
AH-diagnostics).The reactions were performed at 95°C
for 10 min, followed by 40 cycles at 60°C for 1 min,
and 95°C for 30 s. Reaction samples were performed
in duplicates. “No template” and “no reverse tran-
scriptase”controls were included for each reaction plate.
Primers were designed using the NCBI Primer-
BLAST tool (as shown in Supplementary Figure S2).
Primers had no predicted secondary structures of target
sequences using Mfold [26] and were checked for
primer-dimers using AutoDimer [27]. A standard curve
was included for each qPCR reaction plate, and data
were only included if the reaction efficiency fulfilled
the minimum criteria of 100% ± 5 using seven or eight
data points.TATA box-binding protein (TBP) andTy-
rosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein (YWHAZ) were selected as refer-
ence genes due to their stable expression in ASCs with
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increasing passage and at hypoxia [28,29]. The fold
change in gene expression of target genes is shown in
relation to the geometric mean of TBP andYWHAZ
(ΔCq), with 2ΔCq as the fold change in expression levels.
Analysis of significance was performed using 2ΔCq.
β-galactosidase staining
Endogenous β-galactosidase activity was detected using
a β-Gal Staining Kit (Life Technologies) according to
manufacturer’s protocol. In 24-well plates (NUNC,
Thermo Fischer Scientific), 5 × 103 cells/cm2 were
seeded in complete medium containing FBS or hPL.
Preparation of solutions was performed in polystyrene-
free tubes (CELLSTAR, VWR). X-Gal in N,N-
dimethylformamide (Sigma-Aldrich Chemie) was
freshly prepared for each staining. Cells were incu-
bated with staining solution for 24 h at normoxic
conditions. Cells were visualized by bright field mi-
croscopy using an IX51 microscope (Olympus), a
DP71 digital camera (Olympus) and ImageProPlus
7.0 software (Media Cybernetics).
Statistics
All comparisons were initially performed using
repeated-measures analysis of variance.When data were
not dependent on passage number, subsequent anal-
ysis using paired t-test with Sidak correction were
performed. Sidak correction resulted in the signifi-
cance level being set to P < 0.025 for these comparisons
(Figures 4, 5 and 6). Analysis using paired t-test without
Sidak correction was performed due to fewer com-
parisons, resulting in the significance level being set
to P < 0.05 (Figure 3; and Table II). All statistics were
performed with SPSS (IBM). All values are ex-
pressed as mean ± SD unless otherwise stated. All data
is based on ASCs from three donors (n = 3).
Results
Phenotypic characterization
The phenotypes of ASCs P1 were characterized ac-
cording to the ISCT and IFATS guidelines (Table I)
[23,24]. Regardless of culture conditions, ASCs ex-
pressed uniformly high levels (>90%) of stromal
markers CD73, CD90, CD105, CD13, CD29 and
CD166; medium levels (10–30%) of CD36; and low
(2–5%) to very low levels (<2%) of CD45, CD34,
HLA-DR, CD19, CD14, CD106 and CD31.
Morphology
ASCs FBS varied in cell size and shape, with a subset
of cells appearing enlarged and flattened (Figure 2).
ASCs FBS hypoxia contained fewer enlarged cells,
compared with FBS at normoxia. ASCs cultured in
hPL at normoxia and hypoxia appeared homoge-
nous with thin, spindle-like morphologies. The
morphologies of ASCs did not change with increas-
ing passage.
Proliferation kinetics
ASCs expanded in FBS proliferated at low rates
(13.1 ± 0.2 cPDs after seven passages) (Figure 3).
Hypoxia tended to increase the proliferation rates of
FBS-expanded ASCs (18.4 ± 2.6 cPDs), although not
significantly (P = 0.269). hPL significantly increased
the proliferation rates of ASCs, compared with FBS
(24.5 ± 1.9 cPDs, P = 0.014).The proliferation rates
of ASCs hPL hypoxia were also significantly in-
creased compared with FBS (24.3 ± 1.4 cPDs,
P = 0.018). Hypoxia had no effect on the prolifera-
tion rates of ASCs expanded in hPL (P = 1.000).
Cell cycle analysis
The cell cycle distributions of ASCs were investi-
gated by flow cytometry, and the proportion of cells
in G0/G1 phase was used as a measure of non-
cycling cells.
A large proportion of P1 FBS and P1 FBS hypoxia
cultures were in G0/G1 phase (89.1 ± 5.7% and
84.8 ± 4.7%, respectively) (Figure 4). Hypoxia had no
effect on the G0/G1 fraction of P1 FBS cultures
(P = 0.336). The G0/G1 fractions were significantly
lower for P1 hPL and P1 hPL hypoxia, compared with
P1 FBS (52.6 ± 8.8%, P = 0.004 and 52.7 ± 10.9%,
P = 0.010, respectively).
The cell cycle distributions of ASCs FBS, hPL and
hPL hypoxia were similar at P1, P3 and P5, while
hypoxia tended to decrease the G0/G1 fractions of FBS-
expanded ASCs at P3 and P5, compared with P1.
Table I. Surface antigen expression of P1 ASCs cultured in FBS
or hPL at normoxia or hypoxia.
FBS FBS hypoxia hPL hPL hypoxia
CD73 >90% >90% >90% >90%
CD90 >90% >90% >90% >90%
CD105 >90% >90% >90% >90%
CD13 >90% >90% >90% >90%
CD29 >90% >90% >90% >90%
CD166 >90% >90% >90% >90%
CD36 10–30% 10–30% 10–30% 10–30%
CD45 <2% <2% <2% 2–5%
CD34 2–5% <2% 2–5% <2%
HLA-DR <2% <2% <2% 2–5%
CD19 <2% <2% <2% <2%
CD14 2–5% 2–5% <2% <2%
CD106 <2% <2% <2% <2%
CD31 <2% <2% <2% 2–5%
Data are the mean percentage of positive cells from three donors
(n = 3), categorized into groups: > 90%, 10–30%, 2–5% and <2%.
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At P7, the G0/G1 fractions for FBS cultures
(87.7 ± 6.5%) were generally higher compared with
FBS hypoxia, hPL and hPL hypoxia (74.2 ± 5.6%,
75.1 ± 12.8% and 64.3 ± 10.1%, respectively), and the
difference between FBS and hPL hypoxia was signif-
icant (P = 0.008).
Expression of cyclins
The expression of cyclins, which regulate cell cycle
progression, was measured by qPCR.
G1 phase: Overall, the expression levels of the early
G1 phase cyclin D1 tended to be comparable or slightly
higher in FBS and FBS hypoxia, compared with hPL
and hPL hypoxia (Figure 5A). Cyclin D1 levels tended
to increase with increasing passage in FBS hypoxia.
However, no significant differences were found.
The late G1 phase cyclin E1 was expressed
at higher levels in P1 hPL and P1 hPL hypoxia,
compared with P1 FBS and P1 FBS hypoxia (Figure 5B),
with the difference between hPL and FBS being sig-
nificant (P = 0.020). Cyclin E1 levels in FBS remained
low with increasing passage. In contrast, cyclin E1 levels
in FBS hypoxia increased from P3 and onward, com-
pared with P1.The relatively high expression of cyclin
E1 in hPL and hPL hypoxia was maintained with in-
creasing passage. At P7, cyclin E1 levels tended to be
higher in hPL and hPL hypoxia, compared with FBS
(P = 0.060 and P = 0.038, respectively).
S phase: The expression patterns of the S phase
cyclin A2 were similar to the expression patterns of
cyclin E1 (Figure 5C).The only exception was a rel-
ative increase in P1 FBS hypoxia, which was not seen
for cyclin E1. At P1, the expression levels of cyclin
A2 were significantly higher in hPL and hPL hypoxia,
compared with FBS (P = 0.008 and P = 0.001, re-
spectively). The expression levels of cyclin A2 were
similar during serial passaging. At P7, cyclin A2 levels
were significantly higher in hPL hypoxia, compared
with FBS (P = 0.014).
G2/M phase:The expression patterns of the G2/M
phase cyclin B1 were similar to the expression pat-
terns of cyclin A2 (Figure 5D).The expression levels
of cyclin B1 were significantly higher in P1 hPL and
P1 hPL hypoxia, compared with P1 FBS (P = 0.004
and P = 0.007, respectively). At P7, cyclin B1 levels
were significantly higher in hPL hypoxia compared to
FBS (P = 0.021).
Figure 2. Morphology of ASCs expanded in FBS or hPL at normoxia or hypoxia. Scale bar: 200 µm.
Figure 3. Proliferation curves for ASCs P1–P7 expanded in FBS
or hPL at normoxia or hypoxia. Data is shown as mean cPDs ±
SE, based on ASCs from three donors (n = 3). Significance level
is P < 0.05, indicated by *.
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Expression of senescence and quiescence markers
The expression of senescence marker p16INK4A,
senescence and quiescence marker p21 and quies-
cence markers p27 and HES1 was measured by
qPCR.
p21: ASCs FBS expressed relatively high levels
of the cell cycle inhibitor p21, and the levels of p21
did not increase with increasing passage (Figure 6A).
Hypoxia tended to decrease p21 levels in FBS
cultures. Culture in hPL or in hPL at hypoxia also
tended to decrease p21 expression in ASCs P1,
compared with ASCs P1 FBS (P = 0.066 and
P = 0.075, respectively). This trend was maintained
during serial-passaging. At P7, the expression of p21
was significantly lower in hPL and hPL Hypoxia,
compared with FBS (P = 0.009 and P = 0.014,
respectively).
p27: Generally, the expression levels of the cell cycle
inhibitor p27 were higher in FBS and FBS hypoxia
compared with hPL and hPL hypoxia (Figure 6B).
At P5, the p27 expression levels were significantly lower
in hPL, compared with FBS (P = 0.013).
p16INK4A: ASCs generally expressed low levels of
the senescence marker p16INK4A according to different
culture conditions (Figure 6C).There was a small non-
significant increase in p16INK4A expression levels in ASC
FBS hypoxia at P5 and P7, compared with ASCs cul-
tured at the other conditions.This was due to one ASC
donor that generally had higher p16INK4A levels, and
especially in FBS hypoxia at P5 and P7, compared with
the two other ASC donors (Supplementary Figure S3).
HES1:The expression of quiescence marker HES1
showed great variations between ASCs from differ-
ent donors (Figure 6D). Overall, HES1 expression
levels tended to be higher in FBS and FBS hypoxia,
compared with hPL and hPL hypoxia.
Senescence-associated β-galactosidase activity
Regardless of the media supplements FBS and hPL
and oxygen tension, ASCs expanded until P7 were
completely negative for senescence-associated
β-galactosidase activity (data not shown).
Effects of shifting from FBS to hPL or from FBS
hypoxia to hPL hypoxia
The effects of shifting ASCs from FBS to hPL or from
FBS hypoxia to hPL hypoxia can be seen in Figure 7
and Table II.
Morphology: When ASCs were shifted from FBS
to hPL or from FBS hypoxia to hPL hypoxia, they gen-
erally acquired the morphology of hPL-cultured cells,
whereas only a small fraction of cells maintained FBS-
like morphology (Figure 7).
Cell cycle analysis: The shift from FBS to hPL
reduced the G0/G1 fractions of ASCs (60.5 ± 7.3%),
compared to FBS (87.7 ± 6.5%, p = 0.075), as shown
in Table II. This made the G0/G1 fraction of ASCs
FBS to hPL comparable to that of ASCs hPL
(75.1 ± 12.8%).The shift from FBS at hypoxia to hPL
at hypoxia had no effect on G0/G1 fractions
(64.1 ± 8.5%), compared with FBS hypoxia
(75.1 ± 12.8%, P = 0.204).
Expression of cyclins: The shift from FBS to hPL
significantly enhanced expression of cyclin E1
(P = 0.004), cyclin A2 (P = 0.016) and cyclin B1
(P = 0.018), compared with FBS, whereas cyclin D1
expression was not affected (P = 0.374; Table II).The
expression of cyclins in ASCs FBS hypoxia to hPL
hypoxia did not show significant differences com-
pared to FBS hypoxia.
Expression of senescence and quiescence markers: Shift-
ing ASCs from FBS to hPL significantly decreased
Figure 4. Cell cycle distributions of ASCs expanded in FBS or hPL at normoxia or hypoxia. Data is shown as mean percentages of cells
in G0/G1, S, and G2/M phase ± SE, based on ASCs from three donors (n = 3). Significance level is P < 0.025, indicated by *.
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Figure 5. mRNA levels of the four cyclins in ASCs expanded in FBS or hPL at normoxia or hypoxia, and their role in the different cell
cycle phases. (A) Expression of the early G1 phase cyclin D1. (B) Expression of the late G1 phase cyclin E1. (C) Expression of the S
phase cyclin A2. (D) Expression of the G2 and M phase cyclin B1. Data is shown as mean expression levels (2ΔCq) ± SE, based on ASCs
from three donors (n = 3). Significance level is P < 0.025, indicated by *.
Table II. Effects of shifting from FBS to hPL or from FBS hypoxia to hPL hypoxia on G0/G1 fractions and mRNA levels of ASCs P7.
FBS FBS to hPL P value FBS hypoxia FBS hypoxia to hPL hypoxia P value Units
G0/G1 87.7 ± 6.5 60.5 ± 7.3 0.075 74.2 ± 5.6 64.1 ± 8.5 0.204 Percentage
p21 7.96 ± 1.46 1.72 ± 0.54 0.010* 4.99 ± 1.89 1.44 ± 0.24 0.333 Relative expression
p27 0.45 ± 0.13 0.27 ± 0.10 0.032* 0.49 ± 0.39 0.23 ± 0.05 0.129 Relative expression
Cyclin D1 8.97 ± 3.73 6.08 ± 0.70 0.374 14.74 ± 9.27 7.98 ± 3.44 0.201 Relative expression
Cyclin E1 0.05 ± 0.01 0.11 ± 0.01 0.004* 0.10 ± 0.03 0.09 ± 0.04 0.686 Relative expression
Cyclin A2 0.59 ± 0.45 1.58 ± 0.57 0.016* 1.49 ± 0.37 1.12 ± 0.39 0.382 Relative expression
Cyclin B1 0.93 ± 0.61 3.93 ± 1.06 0.018* 2.64 ± 0.43 3.20 ± 1.08 0.435 Relative expression
FBS to hPL data compared with FBS data. FBS hypoxia to hPL hypoxia data are compared with FBS hypoxia data. qPCR data are pre-
sented as 2ΔCq. All data are shown as means ± SD, based on ASCs from three donors (n = 3). *Significance level: P < 0.05.
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expression of p21 (P = 0.010) and p27 (P = 0.032),
compared with FBS (Table II). In contrast, there were
no effects on expression levels of p16INK4A or HES1
(data not shown). The expression of senescence and
quiescence markers in ASCs FBS hypoxia to hPL
hypoxia did not show significant differences com-
pared with FBS hypoxia.
β-galactosidase activity: ASCs FBS to hPL and FBS
hypoxia to hPL hypoxia were completely negative for
β-galactosidase activity (data not shown).
Discussion
This study investigated the effects of the media supple-
ments FBS and hPL and oxygen tension on
proliferation, quiescence and senescence in human
ASCs expanded until P7.
Initially, ASCs P1 cultured in FBS or hPL at
normoxia or hypoxia were characterized according to
the ISCT and IFATS guidelines.The rationale behind
characterizing ASCs P1 was that these were used as
the earliest “time point”/starting point in our subse-
quent analyses. As expected, ASCs P1 contained some
levels of non-stromal cells. However, we think it un-
likely that this affected the results in our subsequent
analyses. Additionally, the levels of non-stromal cells
will diminish with further culture expansion [24].
We found that ASCs culture expanded in FBS pro-
liferated at low rates, had large G0/G1 fractions and
expressed low levels of cyclins E1, A2 and B1 and high
levels of p21. The increasing cPDs with increasing
passage shows that the ASC FBS population as a whole
is proliferating, and hence not senescent or quies-
cent. However, it is possible that senescent or quiescent
subpopulations are present.
Figure 6. mRNA levels of p21, p27, p16INK4A and HES1 in ASCs expanded in FBS or hPL at normoxia or hypoxia. (A) Expression of
senescence and quiescence marker p21. (B) Expression of quiescence marker p27. (C) Expression of senescence marker p16INK4A. (D)
Expression of quiescence marker HES1. Data is shown as mean expression levels (2ΔCq) ± SE, based on ASCs from three donors (n = 3).
Significance level is P < 0.025, indicated by *.
Figure 7. Morphology of ASCs P7 shifted from FBS to hPL or from
FBS hypoxia to hPL hypoxia. Scale bar: 200 µm.
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It has been shown that BMSCs FBS enter repli-
cative senescence at 41 ± 10 cPDs, referred to as the
Hayflick limit [30]. Because BMSCs enter replica-
tive senescence earlier than ASCs, the Hayflick limit
of ASCs is likely to be higher [31]. In our study, the
numbers of reached cPDs were far below the Hayflick
limit, suggesting that ASCs are not replicatively se-
nescent. The lack of expression of p16INK4A, the cell
cycle inhibitor that is especially important for ASC se-
nescence [14,15], further supports that ASCs expanded
until P7 do not contain senescent subpopulations re-
gardless of the media supplements FBS and hPL and
oxygen tension. We did find a non-significant in-
crease in p16INK4A mRNA levels in FBS hypoxia
cultures at P5 and P7, which was due to a relatively
higher p16INK4A level in one ASC donor, compared with
the two other ASC donors. However, because the
p16INK4A protein stabilizes p21 mRNA [32], the lack
of a corresponding increase in p21 mRNA implies that
ASCs expanded until P7 do not express the p16INK4A
protein, regardless of the culture conditions tested here.
It has been shown that p16INK4A mRNA is signifi-
cantly up-regulated in ASCs FBS at 17 cPDs [15].
However, this does not necessarily mean that the
p16INK4A protein is up-regulated.
The final test for reversible cell states versus irre-
versible senescence in our FBS cultures was
rejuvenation with a richer growth medium. Even
though one ASC donor had a higher p16INK4A level
compared with the two other ASC donors, ASCs from
all three donors were able to respond to the mito-
genic stimuli of hPL. Indeed, the shift from FBS to
hPL decreased G1/G0 fractions, significantly en-
hanced expression of cyclins E1, A2 and B1, and
significantly decreased expression of p21 and p27, com-
pared with FBS.Therefore, our ASC product expanded
in FBS until P7 is not irreversibly arrested and hence
not senescent.
The ASCs used in our clinical studies are not ex-
panded beyond P3. On the basis of our findings, we
are certain that the ASC product used in our clinical
studies is senescence-free.
We do not find it relevant for our clinical setting
to determine the passage threshold range at which our
ASC product becomes senescent. On the basis of the
high inter-donor variability in p16INK4A expression, we
predict that the process would be elaborate and
time-consuming.
However, it is likely that ASC donors with higher
p16INK4A levels would reach the senescence thresh-
old earlier than ASC donors with low p16INK4A
levels. Therefore, if ASCs at higher passages than P7
are used clinically, we suggest that screening ASCs
from different donors for p16INK4A expression using
qPCR could provide a useful estimate or prediction
of senescence.
Griffiths et al. demonstrated that the shift from FBS
to hPL completely rejuvenated BMSCs P6–P8, whereas
BMSCs P15–16 only responded transiently to the shift
to hPL, before significantly impaired proliferation was
observed [18]. This suggests a senescence threshold
range for BMSCs around P15–16. If BMSCs FBS
become senescent and show impaired growth factor
responsiveness at P15–P16, the corresponding re-
sponse in ASCs would probably occur at similar or
later passages because BMSCs enter replicative se-
nescence earlier than ASCs [31].
We did not detect any senescence-associated
β-galactosidase activity in ASCs expanded until P7 re-
gardless of the medium supplements FBS and hPL
and oxygen tension. This finding also suggests that
ASCs do not contain senescent subpopulations. An
increase in β-galactosidase activity has been demon-
strated in ASCs FBS at 17 cPDs [15].
The lack of β-galactosidase activity further implies
that ASCs expanded until P7 do not express p16INK4A
because a positive correlation exists between
senescence-associated β-galactosidase activity and ex-
pression of p16INK4A [14].
Because we did not observe any senescent cells in
our FBS cultures, we next investigated whether the
cultures instead contain quiescent populations. Qui-
escent cells (G0) express low levels of cyclins [10].
We found that cyclin D1 levels were comparable in
FBS and hPL cultures, suggesting that ASCs FBS are
in G1 rather than in G0.This implies that ASCs FBS
contain slowly proliferating rather than quiescent sub-
populations, which is also supported by fact that ASCs
FBS proliferate during serial passaging. Alterna-
tively, both of these reversible cell states are present
in FBS cultures.
Cyclin D is a major link between mitogenic sig-
nalling and the cell cycle machinery [7], and therefore
we expected lower levels of cyclin D1 in ASCs FBS.
Because we found that cyclin E1 was lower in FBS
compared with hPL, our results indicate that cyclin
E1 is the rate-limiting cyclin decreasing the rate at
which ASCs FBS progress to S phase. This is sup-
ported by our cell cycle analysis showing that the G0/
G1 phases for FBS were greater than for hPL. Cyclin
E has been shown to be essential for G1/S transition
[7,8], and its transcription might be dependent on mi-
togenic signaling [8,33]. However, the lower levels of
cyclin E1 may not be the only cause of lower prolif-
eration rates in FBS because we also showed that p21
is increased in FBS compared with hPL.
p21 is involved in regulation of proliferation rates
[34] and is expressed by quiescent and senescent cells
[9]. Therefore, the higher p21 levels in FBS are not
necessarily a sign of senescent subpopulations. It has
been shown that mRNA levels of p21 are signifi-
cantly increased in ASCs FBS at 25 cPDs and at P ≥ 15
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[15,35], indicating that p21 levels increase with in-
creasing senescence in ASCs. We did not detect an
increase in p21 mRNA levels in ASCs expanded until
P7, which suggests that expression of p21 in FBS is
due to normal regulation of proliferation rates.We also
found increased levels of p27 in FBS compared with
hPL, although not as pronounced as for p21. This
might be due to regulation of p27 expression at protein
levels.
The transcription factor HES1 ensures that qui-
escent cells do not transit into senescence [11]. We
found great inter-donor variability in expression levels
of HES1, which generally tended to be higher in FBS
compared with hPL. This might suggest that sub-
populations of ASCs FBS are quiescent, whereas other
subpopulations are slowly proliferating. However, a
larger ASC donor size is needed to be able to draw
conclusions. It is also possible that HES1 expression
largely is regulated at protein levels.
Hypoxia tended to increase proliferation rates and
expression of cyclins E1, A2 and B1 and tended to
decrease expression of p21 and G0/G1 fractions in FBS
cultures. Several studies have demonstrated signifi-
cant effects of hypoxia on the proliferation of ASCs
cultured in FBS [3–5].The beneficial effects of hypoxia
possibly include hypoxia-mediated up-regulation of
ASC paracrine activity and decreased accumulation
of reactive oxygen species, compared with expansion
at ambient oxygen levels [2,4,5]. However, the effects
of hypoxia on hPL cultures were similar to the effects
of hPL at normoxia. This implies that hypoxia does
not add to the effect of hPL during ASC expansion
with regard to proliferation, cell cycle regulation and
expression of proliferation-associated genes. Similar
results in BMSCs have been obtained by others [36].
Nevertheless, the effects of hypoxia on the regenera-
tive properties of hPL-expanded ASCs, such as
secretion of vascular endothelial growth factor and
other growth factors, remains to be determined [4,5].
We did not observe significant effects on ASCs FBS
hypoxia shifted to hPL hypoxia. The FBS hypoxia
group was skewed toward the FBS hypoxia to hPL
hypoxia group, and therefore the groups were closer
for all comparisons than FBS and FBS to hPL. This
could explain why we did not observe an effect.
Our qPCR data generally showed tendencies, with
statistical significance at some passages.This is likely
due to the relatively low sample size and high inter-
donor variability.WhereasTBP andYWHAZ have been
proven stabile in ASCs cultured in FBS with increas-
ing passage and at hypoxia [28,29], their stability in
ASCs cultured in hPL remains to be determined.
However, because FBS and hPL had opposing effects
on expression patterns of p21 and cyclins, we do not
expect that altered reference genes contributed to these
effects.
The majority of studies of human mesenchymal
stromal cell senescence have been performed using
BMSCs and, to a lesser extent, ASCs. Here, we have
discussed our results in relation to other ASC studies
when possible, and if not, we have discussed our results
in relation to BMSC studies. However, it is impor-
tant to note that ASCs and BMSCs differ in their
senescence mechanism because BMSCs enter replica-
tive senescence earlier than ASCs [31].Therefore, the
results presented here are potentially only applicable
to ASCs, because we did not directly compare them
to BMSCs. The presence of senescent cells in a clin-
ical ASC product could compromise efficacy [16,17],
and senescent ASCs might acquire a senescence-
associated secretory phenotype [37,38], which probably
interferes with their regenerative effects [39]. There-
fore, a senescence potency assay would contribute to
assurance of cell product quality [40].We have shown
that ASCs expanded until P7 do not contain senes-
cent cells regardless of the media supplements FBS and
hPL and oxygen tension. If ASCs at later passages are
used clinically, we suggest that senescence assessment
should include (i) screening of ASCs from different
donors for p16INK4A expression using qPCR and com-
parison with previously screened donors and (ii) analysis
of responsiveness toward mitogenic stimuli.
Conclusion
Expansion of ASCs in hPL at both normoxia and
hypoxia resulted in enhanced proliferation rates; en-
hanced expression of cyclins E1, A2 and B1; decreased
G0/G1 fractions; and decreased expression of cell cycle
inhibitors p21 and p27 compared with FBS.We con-
clude that hypoxia does not add to the effect of hPL
during ASC expansion with regard to proliferation
rates, cell cycle regulation and proliferation-associated
gene expression. The shift from FBS to hPL en-
hanced expression of cyclins E1, A2 and B1; decreased
expression of p21 and p27; and tended to decrease
G0/G1 fractions. These results show that ASCs FBS
are reversibly arrested and hence not senescent. We
therefore conclude that ASCs expanded until P7 are
not senescent regardless of the media supplements FBS
and hPL and oxygen tension.
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